Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label Study to Evaluate the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer

Next Previous
Trial Profile

A Phase 2, Open-Label Study to Evaluate the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Picibanil (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ADVANCED-2
  • Sponsors Protara Therapeutics

Most Recent Events

  • 08 May 2025 According to a Protara Therapeutics media release, updated interim results (Data cutoff date: as of 16 Apr 2025) from the ADVANCED-2 trial in NMIBC patients with carcinoma in situ or CIS, presented at the American Urological Association (AUA) 2025 Annual Meeting in April.
  • 26 Apr 2025 Interim results presented in the Protara Therapeutics Media Release.
  • 23 Apr 2025 According to a Protara Therapeutics media release, company announced it will host a conference call and live webcast at 8:30 a.m. ET on Monday, April 28, 2025 to review updated safety and efficacy data from the ongoing Phase 2 open-label ADVANCED-2 trial, company will present updated safety and efficacy data from this study at the American Urological Association 2025 Annual Meeting on Saturday, April 26, 2025, at 7:00 a.m. PT.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top